Oryzon Genomics, S.A. announced that the European Patent Office (EPO) has issued an ?intention to grant? communication for Oryzon?s European patent application EP18748921.6 entitled ?Methods of treating behavior alterations? related to vafidemstat, Oryzon?s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.

The allowed claims cover the use of vafidemstat for the treatment of aggression and social withdrawal. The intention to grant is a formal communication from the EPO in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. The patent, once granted, will not expire until at least 2038, excluding any potential patent term extensions that may provide additional protection.

Corresponding patent applications are pending in several additional major pharmaceutical markets, and a patent has already been granted in Russia.